B

BIOFORGE

Section 03

The Opportunity

A convergence of regulatory, technological, and market forces

TL;DR

The longevity market is exploding and the timing is perfect. Medvi proved the market exists and the infrastructure works — a 2-person team generated $401M in revenue using telehealth-as-a-service. But Medvi has a BBB F rating, deepfake ads, and FDA warning letters. We take the same infrastructure but with ethics, compliance, a better product (pre-filled pens), and a premium brand. The FDA just made 14 key peptides legal again. Nobody owns the middle market between cheap apps and geographically limited luxury clinics. BioForge steps in with a full platform — from free quiz to comprehensive peptide protocols — for adults who want to optimize their health and longevity.

FDA Peptide Reclassification — The $12B Unlock

February 27, 2026

HHS Secretary Robert F. Kennedy Jr. announced ~14 of 19 previously Category 2 (banned from compounding) peptides will be moved to Category 1, restoring legal access to compounding.

Peptides Returning to Legal Compounding

BPC-157TB-500 (Thymosin Beta-4)Thymosin Alpha-1AOD-9604CJC-1295IpamorelinGHK-Cu (injectable)SemaxSelankKPVMOTS-CEpitalonKisspeptin-10GHRP-6

This restores a multi-billion dollar market for compounded peptides that was effectively shut down when these peptides were classified as Category 2. Compounding pharmacies under 503A and 503B can legally prepare patient-specific formulations once reclassification is finalized.

⚠ Status: No formal Federal Register notification published yet as of April 2026. Signal of intent from HHS Secretary, not completed regulatory action. Industry already preparing.

Why the Timing is Right

Health Optimization Is Mainstream

The health optimization movement has gone mainstream: Huberman Lab has 5M+ subscribers, Attia's longevity content dominates, r/peptides has 100K+ members. Adults 30-55 are actively seeking recovery, performance, and longevity solutions. Both men and women are investing in proactive health.

Demand Is Latent, Not Aware

Most people don't know they need peptides. Top of funnel = education, not "buy peptides." Content strategy: "Why do you feel tired at 40?", "Why can't you recover like you used to?" The quiz educates and segments. Awareness funnel: Content -> Quiz -> Blood work -> "Now I see my numbers" -> Peptides.

GLP-1 Revolution Created Market Awareness

Ozempic/Wegovy normalized injectable therapeutics. People are now comfortable with self-administered injections and telehealth prescriptions. Pre-filled pens are the next evolution — eliminating the last barrier (reconstitution from vials).

Telehealth Infrastructure Matured

Platforms like CareValidate, OpenLoop, and Wheel provide turnkey telehealth-as-a-service. A single founder with $22K can launch what required $5M and 50 employees in 2020. Medvi proved this at $1.8B scale.

AI + Vibe Coding Destroys Startup Costs

AI tools have collapsed the cost of building a DTC health brand by 90%+. Entire websites, apps, and marketing systems can be vibe-coded at near-zero cost. One person with AI can handle marketing, customer service, content creation, and analytics. The $22K start is real.

The Medvi Precedent

Medvi: Proof of Market, Not Role Model

Founder: Matthew Gallagher, 41, Los Angeles

Jul-Aug 2024

Built Medvi in 2 months with $20,000 and 12+ AI tools

Sep 2024

Launch — 300 customers in month 1

Oct 2024

1,000 additional customers in month 2

2025 (full year)

$401M revenue, 250,000 customers, $65M net profit (16.2% margin)

Feb 2026

Men's health launch — 50,000 customers in first month

Mar 2026

Meal delivery launch; FDA issues 70+ warning letters including to Medvi

Apr 2026

$1.8B annualized run rate ($3M+/day)

revenue2025

$401M

net Profit2025

$65M

margin

16.2%

customers

250,000

revenue Per Customer

$200/month ($1,600/year)

total Cost Base

~$336M

platform Fees

$160-200M (CareValidate/OpenLoop)

marketing Spend

$130-170M

Sam Altman (OpenAI CEO) had a bet with tech CEO friends on when the first one-person billion-dollar company would appear. When Medvi's NYT profile published April 2, 2026, Altman wrote: "it looks like he won that bet" and "would love to meet the guy."